Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat solid cancer tumors.

Type of Molecule

Biologic

Target

cMet

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Solid Tumors New Indication Phase 1